---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-25-000011"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:45:49.711826+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PacBio reports preliminary Q4 revenue $39.2M, down 33% YoY; Vega system shipped ahead of schedule

## Summary
- Preliminary Q4 revenue $39.2M vs $58.4M prior year (-33%); full year $154M vs $200M (-23%).
- Instrument revenue $15.3M (23 Revio, 7 Vega systems); consumables revenue $18.8M flat YoY.
- Launched Vega benchtop system ahead of schedule and SPRQ chemistry enabling sub-$500 HiFi genome.
- Strengthened balance sheet: exchanged $459M of 2028 notes for $200M notes due 2029, 20.5M shares, and $50M cash.
- Preliminary cash and investments $390M as of Dec 31, 2024; final results subject to audit.

## SEC filing metadata
- accession: 0001299130-25-000011
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000011/0001299130-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000011/pacb-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-25-000011
- JSON: https://secwatch.observer/filing/0001299130-25-000011.json
- Plain text: https://secwatch.observer/filing/0001299130-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.